Clinical Trial Detail

NCT ID NCT03628677
Title A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Arcus Biosciences, Inc.
Indications

head and neck squamous cell carcinoma

renal cell carcinoma

breast cancer

Merkel cell carcinoma

urinary bladder cancer

colorectal cancer

ovarian cancer

endometrial cancer

lung non-small cell carcinoma

melanoma

gastroesophageal cancer

Therapies

AB154

AB154 + GLS-010

Age Groups: senior adult

No variant requirements are available.